{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:01:20Z","timestamp":1792684880123,"version":"4.5.0"},"reference-count":183,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is a lethal malignancy with strong ties to chronic liver diseases and metabolic risks. Its pathogenesis involves complex biological processes where disrupted tumor suppressor genes and activated oncogenes drive aberrant signaling pathways and cellular differentiation. Since most patients are diagnosed at advanced stages, only a minority qualify for curative therapies. Although significant therapeutic advances have been made, the overall prognosis remains poor, largely due to high rates of recurrence and metastasis. Therefore, a deeper understanding of HCC\u2019s molecular mechanisms is crucial for developing effective targeted treatments. This review summarizes current insights into HCC pathogenesis and systematically elaborates on contemporary therapies, discussing their respective advantages and limitations.<\/jats:p>","DOI":"10.3389\/or.2026.1763632","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:23:03Z","timestamp":1776403383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["New understanding of the molecular pathogenesis and therapeutic progress of hepatocellular carcinoma"],"prefix":"10.3389","volume":"20","author":[{"given":"Wei-Jun","family":"Wang","sequence":"first","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xia","family":"Yuan","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Zhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Wei","family":"Na","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Ji","family":"He","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Che","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Sheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Gansu Provincial Cancer Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular Carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.semcancer.2021.07.017","article-title":"Epigenetics in hepatocellular carcinoma","volume":"86","author":"Nagaraju","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1053\/j.gastro.2017.02.040","article-title":"Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality","volume":"152","author":"Serper","year":"2017","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/eci.12441","article-title":"The Ras\/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications","volume":"45","author":"Delire","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/cancers12082048","article-title":"Telomeres and telomerase in the development of liver cancer","volume":"12","author":"der Stroth","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s12325-008-0113-z","article-title":"Systemic therapy of hepatocellular carcinoma: are we making progress?","volume":"25","author":"Roxburgh","year":"2008","journal-title":"Adv Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12224","DOI":"10.3390\/ijms241512224","article-title":"Hepatocellular carcinoma: latest research in pathogenesis, detection and treatment","volume":"24","author":"Foglia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1001\/jama.2020.21566","article-title":"Association of hemochromatosis HFE p.C282Y homozygosity with hepatic malignancy","volume":"324","author":"Atkins","year":"2020","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1136\/jclinpath-2012-200791","article-title":"Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up","volume":"65","author":"Stewart","year":"2012","journal-title":"J Clin Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/oxfordjournals.aje.a009745","article-title":"Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden","volume":"149","author":"Linet","year":"1999","journal-title":"Am J Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2021.10.005","article-title":"A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers","volume":"76","author":"Whitfield","year":"2022","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1097\/JS9.0000000000002294","article-title":"Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma","volume":"111","author":"Huang","year":"2025","journal-title":"Int J Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: a review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s1535-6108(04)00058-3","article-title":"Focus on hepatocellular carcinoma","volume":"5","author":"Bruix","year":"2004","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000343836","article-title":"Application of radiotherapeutic strategies in the BCLC-Defined stages of hepatocellular carcinoma","volume":"1","author":"Jihye","year":"2012","journal-title":"Liver Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jtho.2023.10.012","article-title":"The International association for the study of lung cancer staging project for lung cancer: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer","volume":"19","author":"Huang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","article-title":"The international Association for the Study of lung cancer lung cancer staging Project: proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer","volume":"19","author":"Rami-Porta","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients","volume":"56","author":"Okuda","year":"1985","journal-title":"Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/jcp.52.10.725","article-title":"Detection of telomerase in hepatocellular carcinomas using a PCR ELISA assay: comparison with hTR expression","volume":"52","author":"Ferlicot","year":"1999","journal-title":"J Clin Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ng0198-65","article-title":"Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas","volume":"18","author":"Nakayama","year":"1998","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1572-0241.2000.01855.x","article-title":"The role of telomerase activity in hepatocellular carcinoma","volume":"95","author":"Shimada","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41575-019-0165-3","article-title":"The role of telomeres and telomerase in cirrhosis and liver cancer","volume":"16","author":"Nault","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1038\/s41467-018-07552-9","article-title":"Cyclin A2\/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress","volume":"9","author":"Bayard","year":"2018","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ng.3893","article-title":"Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome","volume":"49","author":"Logan","year":"2017","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ng.2295","article-title":"Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma","volume":"44","author":"Sung","year":"2012","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrg2763","article-title":"Alternative lengthening of telomeres: models, mechanisms and implications","volume":"11","author":"Cesare","year":"2010","journal-title":"Nat Rev Genet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/modpathol.2013.68","article-title":"Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features","volume":"26","author":"Wood","year":"2013","journal-title":"Mod Pathol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s12276-020-00527-1","article-title":"Hepatocellular carcinoma: old friends and new tricks","volume":"52","author":"Kim","year":"2020","journal-title":"Exp Mol Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/350429a0","article-title":"Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa","volume":"350","author":"Bressac","year":"1991","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/hep.31175","article-title":"Biomarkers for hepatobiliary cancers","volume":"73","author":"Nault","year":"2021","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nature08137","article-title":"Telomerase modulates Wnt signalling by association with target gene chromatin","volume":"460","author":"Park","year":"2009","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/hep.28638","article-title":"Genotype-phenotype correlation of CTNNB1 mutations reveals different \u00df-catenin activity associated with liver tumor progression","volume":"64","author":"Rebouissou","year":"2016","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","article-title":"Wnt-\u03b2-catenin signalling in liver development, health and disease","volume":"16","author":"Perugorria","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"17216","DOI":"10.1073\/pnas.0404761101","article-title":"Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas","volume":"101","author":"Colnot","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"key":"B49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000496439","article-title":"Systemic treatment for advanced hepatocellular carcinoma","volume":"8","author":"Bouattour","year":"2019","journal-title":"Liver Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/ng.903","article-title":"Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma","volume":"43","author":"Li","year":"2011","journal-title":"Nat Genet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"giy135","DOI":"10.1093\/gigascience\/giy135","article-title":"Advances in genomic hepatocellular carcinoma research","volume":"7","author":"Huang","year":"2018","journal-title":"Gigascience"},{"key":"B53","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J Hepatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"16248","DOI":"10.18632\/oncotarget.7637","article-title":"Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molcel.2014.02.016","article-title":"BRD7, a tumor suppressor, interacts with p85\u03b1 and regulates PI3K activity","volume":"54","author":"Chiu","year":"2014","journal-title":"Mol Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng.3547","article-title":"Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer","volume":"48","author":"Fujimoto","year":"2016","journal-title":"Nat Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2015.11.027","article-title":"Bromodomain containing protein represses the Ras\/Raf\/MEK\/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection","volume":"371","author":"Zhang","year":"2016","journal-title":"Cancer Lett"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1101\/gad.282145.116","article-title":"RB1: a prototype tumor suppressor and an enigma","volume":"30","author":"Dyson","year":"2016","journal-title":"Genes Dev"},{"key":"B59","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer","volume":"19","author":"Kent","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc2401","article-title":"Tailoring to RB: tumour suppressor status and therapeutic response","volume":"8","author":"Knudsen","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1182\/blood-2012-03-415349","article-title":"Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B","volume":"120","author":"Rao","year":"2012","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"114622","DOI":"10.1016\/j.celrep.2024.114622","article-title":"RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4","volume":"43","author":"Weinstein","year":"2024","journal-title":"Cell Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1152\/physrev.00047.2011","article-title":"S-adenosylmethionine in liver health, injury, and cancer","volume":"92","author":"Lu","year":"2012","journal-title":"Physiol Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s12276-025-01415-2","article-title":"Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications","volume":"57","author":"Park","year":"2025","journal-title":"Exp Mol Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"107205","DOI":"10.1016\/j.phrs.2024.107205","article-title":"Epigenetic modulations in triple-negative breast cancer: therapeutic implications for tumor microenvironment","volume":"204","author":"Zhou","year":"2024","journal-title":"Pharmacol Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B68","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome - biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/j.1582-4934.2010.01124.x","article-title":"Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma","volume":"15","author":"Kong","year":"2011","journal-title":"J Cell Mol Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1038\/s41388-022-02213-0","article-title":"Active demethylation upregulates CD147 expression promoting non-small cell lung cancer invasion and metastasis","volume":"41","author":"Liao","year":"2022","journal-title":"Oncogene"},{"key":"B71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-020-01647-2","article-title":"CD147 promotes collective invasion through cathepsin B in hepatocellular carcinoma","volume":"39","author":"Wang","year":"2020","journal-title":"J Exp & Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41467-018-08245-z","article-title":"Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming","volume":"10","author":"Xiong","year":"2019","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","first-page":"102458","DOI":"10.1016\/j.redox.2022.102458","article-title":"GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism","volume":"56","author":"Zhou","year":"2022","journal-title":"Redox Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.7150\/thno.69494","article-title":"Crosstalk between macrophage-derived PGE(2) and tumor UHRF1 drives hepatocellular carcinoma progression","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"B75","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.isci.2024.109821","article-title":"Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma","volume":"27","author":"Zhang","year":"2024","journal-title":"iScience"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1038\/s12276-024-01352-6","article-title":"VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma","volume":"56","author":"Han","year":"2024","journal-title":"Exp Mol Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/HEP.0000000000000875","article-title":"Nuclear KRT19 is a transcriptional corepressor promoting histone deacetylation and liver tumorigenesis","volume":"81","author":"Han","year":"2025","journal-title":"Hepatology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1158\/0008-5472.CAN-17-0988","article-title":"Keratin 19 expression in hepatocellular carcinoma is regulated by fibroblast-derived HGF via a MET-ERK1\/2-AP1 and SP1 axis","volume":"78","author":"Rhee","year":"2018","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nsmb.2848","article-title":"Revolution in the Polycomb hierarchy","volume":"21","author":"Comet","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/bju.12702","article-title":"Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma","volume":"117","author":"Liu","year":"2016","journal-title":"BJU Int"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/sj.bjc.6602531","article-title":"Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma","volume":"92","author":"Sudo","year":"2005","journal-title":"Br J Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e1563","DOI":"10.1002\/ctm2.1563","article-title":"SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation","volume":"14","author":"Su","year":"2024","journal-title":"Clin Transl Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e2411869","DOI":"10.1002\/advs.202411869","article-title":"EIF4A3-Mediated biogenesis of CircFADS1 promotes the progression of hepatocellular carcinoma via Wnt\/\u03b2-Catenin pathway","volume":"12","author":"Tang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.3390\/ijms24087168","article-title":"An Insight into the arising role of MicroRNAs in hepatocellular carcinoma: future diagnostic and therapeutic approaches","volume":"24","author":"Koustas","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B86","doi-asserted-by":"publisher","first-page":"10630","DOI":"10.3390\/ijms221910630","article-title":"The role of long non-coding RNA and microRNA networks in hepatocellular carcinoma and its tumor microenvironment","volume":"22","author":"Shi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.3748\/wjg.v29.i39.5435","article-title":"Function and biomedical implications of exosomal microRNAs delivered by parenchymal and nonparenchymal cells in hepatocellular carcinoma","volume":"29","author":"Wang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.3390\/ijms24043941","article-title":"Emerging role of cancer-associated fibroblasts in progression and treatment of hepatocellular carcinoma","volume":"24","author":"Akk\u0131z","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/hep.31792","article-title":"Cancer-Associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression","volume":"73","author":"Song","year":"2021","journal-title":"Hepatology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41392-024-01887-0","article-title":"Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression","volume":"9","author":"Peng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"B93","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J Clin Invest"},{"key":"B94","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40779-024-00588-7","article-title":"MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies","volume":"12","author":"Tang","year":"2025","journal-title":"Mil Med Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"key":"B96","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12943-024-02049-0","article-title":"Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy","volume":"23","author":"Tang","year":"2024","journal-title":"Mol Cancer"},{"key":"B97","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-333944","article-title":"E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression","author":"Zhang","year":"2025","journal-title":"Gut"},{"key":"B98","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-024-02985-1","article-title":"S100A9(+)CD14(+) monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function","volume":"43","author":"Tu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B99","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2025-335078","article-title":"ETV5-S100A9 feed-forward loop connecting HCC and MDSCs to shape the immunosuppressive tumour microenvironment","author":"Wong","year":"2025","journal-title":"Gut"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"B101","doi-asserted-by":"publisher","first-page":"101130","DOI":"10.1016\/j.jhepr.2024.101130","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"6","author":"Childs","year":"2024","journal-title":"JHEP Rep"},{"key":"B102","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.gastro.2024.02.025","article-title":"TGF-\u03b21-Induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12","volume":"167","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/s41467-024-45823-w","article-title":"Pro-ferroptotic signaling promotes arterial aging via vascular smooth muscle cell senescence","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"B104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.canlet.2010.10.022","article-title":"Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB","volume":"301","author":"Ma","year":"2011","journal-title":"Cancer Lett"},{"key":"B105","first-page":"1145","article-title":"Fas stimulation activates NF-kappaB in SK-Hep1 hepatocellular carcinoma cells","volume":"10","author":"Okano","year":"2003","journal-title":"Oncol Rep"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e108507","DOI":"10.1371\/journal.pone.0108507","article-title":"RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-kappaB-mediated epithelial-mesenchymal transition","volume":"9","author":"Song","year":"2014","journal-title":"PLoS One"},{"key":"B107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-020-01028-4","article-title":"Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism","volume":"14","author":"Zhou","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1038\/onc.2013.243","article-title":"Snail1-dependent transcriptional repression of Cezanne2 in hepatocellular carcinoma","volume":"33","author":"Xu","year":"2014","journal-title":"Oncogene"},{"key":"B109","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/tox.23691","article-title":"PI3K\/AKT\/mTOR pathway mediated-cell cycle dysregulation contribute to malignant proliferation of mouse spermatogonia induced by microcystin-leucine arginine","volume":"38","author":"Du","year":"2023","journal-title":"Environ Toxicol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1242\/dev.137075","article-title":"Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination","volume":"143","author":"Yu","year":"2016","journal-title":"Development"},{"key":"B111","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2018.04.072","article-title":"Inhibition of PI3K\/Akt\/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells","volume":"103","author":"Yang","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"B112","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12967-024-04870-z","article-title":"Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K\/AKT\/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms","volume":"22","author":"Gu","year":"2024","journal-title":"J Transl Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"B114","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40164-021-00227-0","article-title":"YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K\/AKT\/mTOR signaling pathway and inducing epithelial-mesenchymal transition","volume":"10","author":"Luo","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/biomedicines9111639","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in hepatocellular carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"Biomedicines"},{"key":"B116","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10555-023-10156-5","article-title":"Regulation and targeting of SREBP-1 in hepatocellular carcinoma","volume":"43","author":"Su","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"B117","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12967-025-06537-9","article-title":"AP5Z1 affects hepatocellular carcinoma growth and autophagy by regulating PTEN ubiquitination and modulating the PI3K\/Akt\/mTOR pathway","volume":"23","author":"Quan","year":"2025","journal-title":"J Transl Med"},{"key":"B118","first-page":"7940","article-title":"IL-9 promotes proliferation and metastasis of hepatocellular cancer cells by activating JAK2\/STAT3 pathway","volume":"10","author":"Lei","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e2306623","DOI":"10.1002\/advs.202306623","article-title":"Targeting C21orf58 is a novel treatment strategy of hepatocellular carcinoma by disrupting the Formation of JAK2\/C21orf58\/STAT3 complex","volume":"11","author":"Jiang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41388-024-03271-2","article-title":"STK31 drives tumor immune evasion through STAT3-IL-6 mediated CD8(+) T cell exhaustion","volume":"44","author":"Li","year":"2025","journal-title":"Oncogene"},{"key":"B121","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41419-024-07095-6","article-title":"GPR56 facilitates hepatocellular carcinoma metastasis by promoting the TGF-beta signaling pathway","volume":"15","author":"Luo","year":"2024","journal-title":"Cell Death Dis"},{"key":"B122","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccell.2014.11.025","article-title":"14-3-3zeta turns TGF-beta's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2","volume":"27","author":"Xu","year":"2015","journal-title":"Cancer Cell"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e2401013","DOI":"10.1002\/advs.202401013","article-title":"m(6)A-Dependent ITIH1 regulated by TGF-beta acts as a target for hepatocellular carcinoma progression","volume":"11","author":"Liao","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","article-title":"Disruption of TGF-beta signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells","volume":"31","author":"Thangaraj","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"111891","DOI":"10.1016\/j.cellsig.2025.111891","article-title":"Primary cilium restricts TGF-beta\/SMAD signaling induced RIBEs in the co-culture model","volume":"134","author":"Qu","year":"2025","journal-title":"Cell Signal"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.ajpath.2018.07.022","article-title":"High frequency of beta-catenin mutations in Mouse hepatocellular Carcinomas induced by a nongenotoxic constitutive androstane receptor agonist","volume":"188","author":"Mattu","year":"2018","journal-title":"Am J Pathol"},{"key":"B127","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cmet.2019.01.002","article-title":"Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by beta-catenin mutations","volume":"29","author":"Adebayo Michael","year":"2019","journal-title":"Cell Metab."},{"key":"B128","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jphs.2018.01.003","article-title":"Oligo-peptide I-C-F-6 inhibits hepatic stellate cell activation and ameliorates CCl(4)-induced liver fibrosis by suppressing NF-kappaB signaling and Wnt\/beta-catenin signaling","volume":"136","author":"Sun","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"B129","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-025-03447-4","article-title":"Cancer-associated loss-of-function mutations in KCNQ1 enhance Wnt\/beta-catenin signalling disrupting epithelial homeostasis","author":"Berenguier","year":"2025","journal-title":"Oncogene"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.aaw9886","article-title":"Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice","volume":"366","author":"Moya","year":"2019","journal-title":"Science"},{"key":"B131","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ceb.2019.07.006","article-title":"Role of the transcriptional coactivators YAP\/TAZ in liver cancer","volume":"61","author":"Zhang","year":"2019","journal-title":"Curr Opin Cell Biol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3892\/ol.2016.5110","article-title":"The Ras\/Raf\/MEK\/ERK signaling pathway and its role in the occurrence and development of HCC","volume":"12","author":"Li","year":"2016","journal-title":"Oncol Lett"},{"key":"B133","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1038\/s41467-024-46521-3","article-title":"The EIF3H-HAX1 axis increases RAF-MEK-ERK signaling activity to promote colorectal cancer progression","volume":"15","author":"Jin","year":"2024","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cell.2019.07.031","article-title":"The oncogenic action of NRF2 depends on De-glycation by Fructosamine-3-Kinase","volume":"178","author":"Sanghvi","year":"2019","journal-title":"Cell"},{"key":"B136","doi-asserted-by":"publisher","first-page":"e50854","DOI":"10.15252\/embr.202050854","article-title":"MOAP-1-mediated dissociation of p62\/SQSTM1 bodies releases Keap1 and suppresses Nrf2 signaling","volume":"22","author":"Tan","year":"2021","journal-title":"EMBO Rep"},{"key":"B137","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41420-023-01752-z","article-title":"Cepharanthine, a regulator of keap1-Nrf2, inhibits gastric cancer growth through oxidative stress and energy metabolism pathway","volume":"9","author":"Lu","year":"2023","journal-title":"Cell Death Discov"},{"key":"B138","doi-asserted-by":"publisher","first-page":"111396","DOI":"10.1016\/j.brainresbull.2025.111396","article-title":"Therapeutic time window of Sodium of Danshensu on cerebral ischemia and its mechanism of inhibiting oxidative stress and ferroptosis through Nrf2 pathway","volume":"227","author":"Guo","year":"2025","journal-title":"Brain Res Bull"},{"key":"B139","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3892\/ol.2024.14575","article-title":"Sonic hedgehog expression in steatohepatitic hepatocellular carcinoma and its clinicopathological significance","volume":"28","author":"Kusano","year":"2024","journal-title":"Oncol Lett."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3892\/or.2013.2690","article-title":"Role of the Hedgehog pathway in hepatocellular carcinoma (review)","volume":"30","author":"Zheng","year":"2013","journal-title":"Oncol Rep"},{"key":"B141","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1515\/hsz-2018-0131","article-title":"Upregulation of Twist is involved in Gli1 induced migration and invasion of hepatocarcinoma cells","volume":"399","author":"Li","year":"2018","journal-title":"Biol Chem"},{"key":"B142","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1615\/CritRevOncog.2020034985","article-title":"Targeted molecular therapeutic options for hepatocellular carcinoma","volume":"25","author":"Sridhar","year":"2020","journal-title":"Crit Rev Oncog"},{"key":"B143","doi-asserted-by":"publisher","first-page":"217061","DOI":"10.1016\/j.canlet.2024.217061","article-title":"Hepatocellular carcinoma and lipid metabolism: novel targets and therapeutic strategies","volume":"597","author":"Cao","year":"2024","journal-title":"Cancer Lett."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e2301149","DOI":"10.1002\/smll.202301149","article-title":"Butyrate modification promotes intestinal absorption and hepatic cancer cells targeting of ferroptosis inducer loaded nanoparticle for enhanced hepatocellular carcinoma therapy","volume":"19","author":"Yu","year":"2023","journal-title":"Small"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2473504","DOI":"10.1080\/19490976.2025.2473504","article-title":"The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma","volume":"17","author":"Yao","year":"2025","journal-title":"Gut Microbes"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B147","doi-asserted-by":"publisher","first-page":"104735","DOI":"10.1016\/j.critrevonc.2025.104735","article-title":"Targeting TIME in advanced hepatocellular carcinoma: mechanisms of drug resistance and treatment strategies","volume":"211","author":"Ye","year":"2025","journal-title":"Crit Rev Oncol Hematol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"104737","DOI":"10.1016\/j.critrevonc.2025.104737","article-title":"Post-treatment adverse events ranking in targeted immunotherapy for hepatocellular carcinoma: a network meta-analysis based on risk probability assessment","volume":"211","author":"Yang","year":"2025","journal-title":"Crit Rev Oncol Hematol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","article-title":"Inhibition of EGFR overcomes acquired Lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma","volume":"82","author":"Hu","year":"2022","journal-title":"Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","article-title":"Lenvatinib: a review in hepatocellular carcinoma","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"B151","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B153","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1489649","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/med.21455","article-title":"Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment","volume":"38","author":"Zhou","year":"2018","journal-title":"Med Res Rev"},{"key":"B158","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cytogfr.2024.08.006","article-title":"Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis","volume":"79","author":"Yu","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"B159","doi-asserted-by":"publisher","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med J."},{"key":"B160","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrmicro2872","article-title":"Understanding and learning from the success of prophylactic human papillomavirus vaccines","volume":"10","author":"Schiller","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"B162","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-022-01266-8","article-title":"Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses","volume":"15","author":"Zuo","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"217680","DOI":"10.1016\/j.canlet.2025.217680","article-title":"The arginine metabolism and its deprivation in cancer therapy","volume":"620","author":"Feng","year":"2025","journal-title":"Cancer Lett."},{"key":"B165","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2004.10.050","article-title":"Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma","volume":"224","author":"Cheng","year":"2005","journal-title":"Cancer Lett"},{"key":"B166","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41565-022-01129-w","article-title":"Characterization of nanoparticles-based vaccines for COVID-19","volume":"17","author":"Guerrini","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"B167","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B168","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","article-title":"Non-viral vectors for RNA delivery","volume":"342","author":"Yan","year":"2022","journal-title":"J Control Release"},{"key":"B169","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jconrel.2023.10.034","article-title":"Bioengineered nanotechnology for nucleic acid delivery","volume":"364","author":"Zhang","year":"2023","journal-title":"J Control Release"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.7150\/thno.18136","article-title":"Surface De-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo","volume":"7","author":"Zhu","year":"2017","journal-title":"Theranostics"},{"key":"B171","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1166\/jbn.2021.3033","article-title":"Targeted delivery of Glypican 3 (GPC3) antibody-modified MicroRNA (miR let-7b-5p) polymer nanoparticles to Sorafenib-Resistant hepatsocellular carcinoma cells","volume":"17","author":"Zhou","year":"2021","journal-title":"J Biomed Nanotechnol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"965","DOI":"10.7150\/thno.102964","article-title":"RNA nanotherapeutics for hepatocellular carcinoma treatment","volume":"15","author":"Yuan","year":"2025","journal-title":"Theranostics"},{"key":"B173","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.actbio.2019.08.046","article-title":"Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer","volume":"99","author":"Liu","year":"2019","journal-title":"Acta Biomater"},{"key":"B174","doi-asserted-by":"publisher","first-page":"119760","DOI":"10.1016\/j.biomaterials.2020.119760","article-title":"Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials"},{"key":"B175","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","article-title":"MTL-CEBPA, a small activating RNA therapeutic upregulating C\/EBP-\u03b1, in patients with advanced liver cancer: a First-in-Human, multicenter, Open-Label, phase I trial","volume":"26","author":"Sarker","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5152\/tjg.2024.24325","article-title":"Harnessing the power of AI for enhanced diagnosis and treatment of hepatocellular carcinoma","volume":"36","author":"Jin","year":"2024","journal-title":"Turk J Gastroenterol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jhep.2022.01.014","article-title":"Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma","volume":"76","author":"Calderaro","year":"2022","journal-title":"J Hepatol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"S882","DOI":"10.21037\/jtd.2018.03.81","article-title":"Liquid biopsy for lung cancer early detection","volume":"10","author":"Santarpia","year":"2018","journal-title":"J Thorac Dis"},{"key":"B179","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbrc.2007.06.172","article-title":"Artificial neural networks and decision tree model analysis of liver cancer proteomes","volume":"361","author":"Luk","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B180","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jamcollsurg.2013.11.006","article-title":"Application of surgical safety standards to robotic surgery: five principles of ethics for nonmaleficence","volume":"218","author":"Larson","year":"2014","journal-title":"J Am Coll Surg"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1109\/TBME.2014.2302385","article-title":"Smart tissue anastomosis robot (STAR): a vision-guided robotics system for laparoscopic suturing","volume":"61","author":"Leonard","year":"2014","journal-title":"IEEE Trans Biomed Eng"},{"key":"B182","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijsu.2020.05.070","article-title":"Robotic liver resection: hurdles and beyond","author":"Di Benedetto","year":"2020","journal-title":"Int J Surg"},{"key":"B183","doi-asserted-by":"publisher","first-page":"478","DOI":"10.21037\/hbsn.2016.05.05","article-title":"Laparoscopic and robotic approach for hepatocellular carcinoma-state of the art","volume":"5","author":"Levi Sandri","year":"2016","journal-title":"Hepatobiliary Surg Nutr"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1763632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:23:06Z","timestamp":1776403386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1763632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":183,"alternative-id":["10.3389\/or.2026.1763632"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1763632","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1763632"}}